| Literature DB >> 15969744 |
Cengiz Bolukbas1, Fusun F Bolukbas, Tulin Kendir, Remzi A Dalay, Nihat Akbayir, Mehmet H Sokmen, Ali T Ince, Mithat Guran, Erkan Ceylan, Guray Kilic, Oya Ovunc.
Abstract
BACKGROUND: The accurate diagnosis of abdominal tuberculosis usually takes a long time and requires a high index of suspicion in clinic practice. Eighty-eight immune-competent patients with abdominal tuberculosis were grouped according to symptoms at presentation and followed prospectively in order to investigate the effect of symptomatic presentation on clinical diagnosis and prognosis.Entities:
Mesh:
Year: 2005 PMID: 15969744 PMCID: PMC1183200 DOI: 10.1186/1471-230X-5-21
Source DB: PubMed Journal: BMC Gastroenterol ISSN: 1471-230X Impact factor: 3.067
Demographic and clinic features in whole group.
| Patients, (n) | 88 |
| Age (year) | 31.4 ± 15 |
| Gender (F/M) | 48/40 |
| Disease duration (month) | 10.4 ± 19 |
| Main symptom (n/%) | |
| Abdominal pain | 25 (28.4%) |
| Abdominal distension | 23 (26.1%) |
| Diarrhea | 15 (17%) |
| Fever | 4 (4.5%) |
| Weight loss | 4 (4.5%) |
| Ileus | 4 (4.5%) |
| Perforation | 4 (4.5%) |
| Others | 4 (4.5%) |
| Dysphagia | 2 (2.3%) |
| Icter | 2 (2.3%) |
| Dyspepsia | 1 (1.1%) |
| Previous history for TB | 15 (17%) |
| Family history for TB | 8 (9.1%) |
F, Female; M, Male; TB, Tuberculosis.
The results of the diagnostic methods in whole group.
| ESR (mm/h) | 68 ± 24 |
| CRP (mg/L) | 53 ± 39 |
| WBC (/mm3 × 1000) | 9.2 ± 3.6 |
| Hct % | 32.3 ± 5.2 |
| Hb (g/dL) | 10.6 ± 1.9 |
| Chest X-ray % | |
| Active lesion | 24 (27.3%) |
| Lesion consistent with prior TB | 15 (17%) |
| Normal | 49 (55.7%) |
| AFB positivity in sputum % | 11 (12.6%) |
| Lesion frequency in abdominal plain graphs % | 21 (23.9%) |
| Abdominal US abnormality* | 78 (88.6%) |
*Including hepatomegaly-splenomegaly
ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; WBC, white blood cell count;
Hct, haemotocrit; Hb, haemoglobin; AFB, acid-fast bacteria; US, ultrasonography.
Demographic and clinical features in divided groups based upon the clinical presentation.
| Groups* | I (n = 24) | II (n = 24) | III (n = 22) | IV (n = 9) | V (n = 9) | P |
| Age (yr) | 36.5 ± 20 | 30.4 ± 13 | 23.5 ± 8 | 32.7 ± 12 | 38 ± 16 | 0.048 |
| Gender (F/M) | 12/12 | 13/11 | 14/8 | 2/7 | 5/4 | 0.34 |
| Disease Duration (mo) | 11.3 ± 23 | 6 ± 8 | 9.8 ± 14 | 25 ± 41 | 6.6 ± 5 | 0.869 |
| Previous history of TB % | 16.7 | 8.3 | 18.2 | 22.2 | 33.3 | 0.530 |
| Family history for TB % | 8.3 | 4.2 | 18.2 | 11.1 | 0 | 0.425 |
| Weight loss (kg) | 8.2 ± 7 | 6 ± 4.5 | 8.5 ± 6 | 8.7 ± 5 | 8.1 ± 7.2 | 0.496 |
| Temperature (°C) | 37.5 ± 1 | 37.4 ± 0.8 | 37.5 ± 1 | 37.9 ± 0.9 | 37.2 ± 1 | 0.615 |
| Fistula (%)* | 8.3 | 0 | 31.8 | 0 | 22.2 | 0.07 |
| Therapeutic Operation % | 33.3 | 12.5 | 27.3 | 66.6 | 22.2 | 0.001 |
| Response to therapy % | 91.7 | 95.8 | 90.9 | 77.7 | 100 | 0.354 |
| First response to therapy (mo) | 2.5 ± 1.5 | 2.1 ± 1.6 | 1.9 ± 1.3 | 2.6 ± 1.5 | 2.8 ± 2 | 0.298 |
| Death % | 8.3 | 4.2 | 4.5 | 11.1 | 0 | 0.825 |
*Group I, non-specific abdominal pain; Group II, ascites; Group III, alteration in bowel habit (diarrhea, constipation or together); Group IV, acute abdomen; Group V, others (jaundice, dysphagia, fistula, fever of unknown origin, mass, weight loss);
Yr, year; F, female; M, male; Mo, month; TB, tuberculosis.
P value of less than 0.05 was considered to indicate the statistical significance in between groups.
The results of the diagnostic laboratory methods, the rate of abnormality in imaging and invasive methods, and definitive diagnosis in divided groups based upon the clinical presentation.
| Groups* | I (n = 24) | II (n = 24) | III (n = 22) | IV (n = 9) | V (n = 9) | P |
| WBC (/mm3 × 1000) | 10 ± 4 | 8.7 ± 2.6 | 7.7 ± 1.8 | 14 ± 3.7 | 7.3 ± 2.8 | 0.002 |
| ESR(mm/h) | 67 ± 21 | 65 ± 31 | 71 ± 20 | 69 ± 21 | 72 ± 26 | 0.842 |
| Tuberculin skin test (mm) | 17 ± 7 | 18 ± 6.5 | 13 ± 7 | 18 ± 11 | 16 ± 9 | 0.119 |
| AFB in sputum % | 12.5 | 4.5 | 18.2 | 25 | 11 | 0.602 |
| Chest X-ray % | 54.2 | 27.5 | 40.9 | 66.6 | 22.2 | 0.448 |
| APG % | 20.8 | 12.5 | 31.8 | 66.7 | 0 | 0.014 |
| Abdominal CT % | 91.7 | 100 | 90.9 | 100 | 77.8 | 0.196 |
| ** Colonoscopy % | 62.5 (5/8) | 7.5 (2/15) | 90.9 (20/22) | 75 (3/4) | 33.3 (1/3) | 0.04 |
| Operation % | 54.2 | 54.2 | 33.3 | 75 | 22.2 | 0.156 |
| Diagnosis % | ||||||
| Evidence based | 79.2 | 83.3 | 86.4 | 88.9 | 88.9 | |
| Histopathologic | 62.5 | 50 | 45.5 | 44.4 | 55.6 | |
| Microbiologic | 4.2 | 12.5 | 9.1 | 33.3 | 11.1 | 0.933 |
| H+M | 12.5 | 20.8 | 31.8 | 11.1 | 22.2 | |
| ETT% | 20.8 | 16.7 | 13.6 | 11.1 | 11.1 | |
*Group I, non-specific abdominal pain; Group II, ascites; Group III, alteration in bowel habit (diarrhea or constipation or together); Group IV, acute abdomen; Group V, others (jaundice, dysphagia, fistula, fever of unknown origin, mass, weight loss);
** The percent in patients with colonoscopy performed WBC, white blood cell count; ESR, erythrocyte sedimentation rate; AFB, acid-fast bacteria; APG, abdominal plain graphy; CT, computed tomography; H, histopathologic; M, microbiologic; ETT, empiric therapeutic trial. P value of less than 0.05 was considered to indicate the statistical significance in between groups.
The distribution of involvement area in the groups*.
| Localization | Group I (n = 24) | Group II (n = 24) | Group III (n = 22) | Group IV (n = 9) | Group V (n = 9) | Total (n) |
| Multiple (n) (Peritoneum, SB, colon, pericardium) | 2 | 7 | 6 | 1 | 2 | 18 |
| GI Tract (n) | 34 | |||||
| SB | 3 | 2 | 1 | |||
| Ileocecal | 6 | 7 | 5 | |||
| Colon | 6 | 1 | ||||
| Stomach | 1 | |||||
| Esophagus | 2 | |||||
| Liver | 3 | 1 | 4 | |||
| Peritoneum | 8 | 17 | 25 | |||
| Mesenteric LAP | 3 | 2 | 5 | |||
| Pancreas and biliary system | 1 | 1 | 2 | |||
| Total (n) | 24 | 24 | 22 | 9 | 9 | 88 |
*Group I, non-specific abdominal pain; Group II, ascites; Group III, alteration in bowel habit (diarrhea or constipation or together); Group IV, acute abdomen; Group V, others (jaundice, dysphagia, fistula, fever of unknown origin, mass, weight loss);
SB, small bowel; GI, gastrointestinal; LAP, lymphadenopathy